@rider51

Wow that’s an amazing result!

Duke University has been using ExoDx for more than five years and it has helped them discern some clinically significant PCa in cases like yours.

However, ExoDx results don’t always predict what may be found in the biopsy and it may turn out that ExoDx is actually a better predictor of clinically significant PCa than a biopsy!

This video describes some of Duke’s findings.

I was particularly interested in their Case 3 vs Case 4 (15:30 - 22:00 of video).

In Case #3 the patient had a PSA of 4.7 and an ExoDx score of 21.4%, but Gleason 4+5 and 4+4 were found in 12 of 12 cores.

Conversely, in case #4, the patient had a PSA of 4.4 and an ExoDx score of 89.3% and yet the biopsy only found Gleason 3+3. The author thinks they may have missed the clinically significant PCa in their biopsy and was planning another biopsy because of the higher ExoDx score.

All that to say, it would be ironic if a test such as ExoDx turns out to be a better predictor of the presence of clinically significant prostate cancer than a biopsy!